Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS

Next Previous
Trial Profile

Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasudil (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Proof of concept
  • Acronyms ROCK-ALS

Most Recent Events

  • 09 Jan 2025 According to the Raya Therapeutic Media Release, In December 2024, company announced the presentation of data from this study at the 35th International Symposium on ALS/MND in Montreal.
  • 01 Nov 2024 Results investigating safety, tolerability, and efficacy of fasudil in patients with amyotrophic lateral sclerosis published in the Lancet Neurology.
  • 17 Jun 2024 According to Raya Therapeutic media release, data from the study were presented in a conference abstract for the ENCALS meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top